Informazioni sulla prescrizione
1) DaTSCAN-riassunto delle caratteristiche del prodotto
2) GE Healthcare. “Driving Excellence in DaT imaging”Data 2.
3) Booij et al. Diagnostic performance of the visual reading of 123I-ioflupane SPECT images when assessed with or without quantification in patients with movement disorders or dementia. Journal of Nuclear Medicine, May 4 2017 as doi:10.2967/jnumed.116.189266
4) Suwijin et al. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Research 2015 5:12
5)Bajaj N, Birchall J, Jones I. What is the false positive and negative rate of FP-CIT in clinical practice? Presented in Neuroimaging section, June 12, (2012), 16th International Movement Disorder Society Meeting; Dublin, Ireland (Abstract 694)
6) Grosset et al. Study Analysis of 10 Clinical Trials for 13 years after first approval of ioflupane 123I injection (DaTscan). J Nuc Med 2014:55:1-7.
Immagini originali
Immagine 5 di Booij et al.
JB00607IT Dep in AIFA il 14/07/2021 DaTSCAN-Classe C-OSP-P.P.:Confezione da 2,5 ml € 2.177,43-Confezione da 5ml € 3.380,00